Two-component gastric ultrasound examination auxiliary developer and preparation method thereof

The two-component gastric ultrasound developer addresses issues of stability and gas expulsion by using biocompatible polymer-modified silica particles to create a uniform interface for enhanced gastric ultrasound diagnostics with reduced artifacts and extended inspection time.

JP7595194B2Active Publication Date: 2024-12-05SHANDONG BRANDEN MEDICAL DEVICE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2023576105
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-10-13
Filing Date
2023-04-12
Publication Date
2024-12-05
Estimated Expiration
2043-04-12

AI Technical Summary

Technical Problem

Current gastric ultrasound examination auxiliary developers face issues with poor development effects, stability, and gas expulsion, leading to artifacts and insufficient inspection time due to mismatched solid contrast particle sizes and densities, as well as complex preparation processes.

Method used

A two-component gastric ultrasound examination auxiliary developer comprising component A with functional silica particles, antifoaming agents, and sodium alginate, and component B with calcium chloride, ensuring uniform dispersion and increased viscosity for stable adhesion to the gastric wall, expelling gas quickly and extending inspection time.

Benefits of technology

The developer provides a uniform and stable interface for gastric ultrasound, effectively reducing gas artifacts and ensuring sufficient inspection time by using biocompatible polymer-modified silica particles that adhere to the gastric wall, enhancing diagnostic accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595194000004
    Figure 0007595194000004
  • Figure 0007595194000001
    Figure 0007595194000001
  • Figure 0007595194000002
    Figure 0007595194000002
Patent Text Reader

Abstract

The present invention discloses a two-component gastric ultrasound examination auxiliary developer and its preparation method, which belong to the technical field of medical image diagnosis. The auxiliary developer is composed of two components, component A is composed of functional silica particles, antifoaming agent, sodium alginate, citric acid and water, and component B is a calcium chloride solution. During the examination, component A with low viscosity is used first, and gas is rapidly discharged while filling the stomach, reducing the interference of gas artifacts, and at the same time, the functional silica particles are rapidly dispersed in the stomach wall with the peristalsis of the stomach, and under the action of aldehyde groups or sulfhydryl groups and alcohol-soluble proteins, they adhere to the lipoprotein layer of the stomach wall, forming a uniform and highly echogenic interface in the stomach wall, which can improve the diagnosis rate of diseases. After 3 minutes from the use of component A, component B is used, and the viscosity of the auxiliary developer increases in 1 to 3 minutes, the window time is extended, and sufficient examination time can be ensured. Therefore, the present invention is expected to solve the problems of unclear contrast, short window time, or inability to remove gas artifacts in stomach wall examination, and has good application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a gastric ultrasound examination auxiliary developer and its preparation method, which belongs to the technical field of medical ultrasound examination. [Background technology]

[0002] The stomach occupies 3 / 4 of the abdominal cavity volume, constitutes the majority of the digestive tract, and is the most morbid organ in the digestive system, and is one of the most clinically morbid organs. To clarify the location and nature of lesions, various examination methods are often used as diagnostic aids. Gastric examination methods include upper gastrointestinal barium diet, gastroscopy, gastric CT, and MRI. Upper gastrointestinal barium diet is simple, painless, and easy for patients to accept, but barium diet is a radioactive substance, and the results depend on the barium coating and filling effect, as well as the experience of the examiner. Barium sulfate is relatively safe, but there are a small number of patients who experience side effects and complications such as allergies, barium poisoning, barium leakage, barium sulfate fecal stone embedment, and worsening constipation, and some cases may even lead to death. Therefore, clinical application is limited, especially in elderly patients, patients with constipation, pregnant women, barium allergies, and patients with acute upper gastrointestinal bleeding, and barium diet X-ray is not used as a routine diagnostic aid. Gastroscopy can depict the shape and color of the gastric mucosa, the location, size, and depth of the lesion, and can perform pathological examinations to observe the lesions under direct vision and clarify the nature of the lesions. However, gastroscopy can only show the structure of the lumen well, and cannot observe the layers of the stomach wall or the peristaltic movement of the stomach. Since gastroscopy is an interventional examination, most people, such as elderly patients with severe cardiopulmonary disease, patients in the acute stage of upper gastrointestinal perforation, patients with acute severe pharyngeal disease, patients in the acute stage of corrosive esophageal damage, and patients who cannot cooperate due to mental disorders, experience discomfort that cannot be tolerated by gastroscopy, which subjectively and objectively limits the application of gastroscopy. CT / MRI, which has high spatial resolution and clear anatomical structures, is an imaging diagnostic method often used for staging gastric cancer, but CT / MRI is not easily used to detect microlesions in the gastric lumen and has low diagnostic value for other gastric diseases, so it is not used as a routine examination method.

[0003] Since the discovery of the piezoelectric effect and the converse piezoelectric effect in physics in the early 20th century, ultrasound has rapidly opened a chapter in the history of technology and become a common and important examination method in the solid organs of the digestive system due to its non-invasive, painless, inexpensive, well tolerated and non-radioactive nature.

[0004] At present, there are three types of gastric ultrasound examinations used in clinical practice: transabdominal ultrasound examination, gastric filling ultrasound examination, and endoscopic ultrasound examination. Transabdominal ultrasound examination is merely an examination for preliminary screening, while endoscopic ultrasound examination combines the advantages of endoscopy and ultrasound examination to compensate for their respective shortcomings, further improving the diagnostic level of endoscopy and ultrasound examination. However, due to its high cost, complicated operation, and certain trauma, it is limited to some large hospitals and is far from being popularized. Gastric filling ultrasound examination is a method of filling the gastric cavity with contrast agent (also called auxiliary developer) to eliminate the interference of ultrasound caused by gastric gas and contents, improve the internal environment of gastric ultrasound examination, and more clearly depict the structure and lesions of the stomach wall. This is the development trend of ultrasound examination for gastric diseases and can be popularized. Contrast agents are mainly non-echoic aqueous type and echoic powder type, and the current application is mainly echoic powder type.

[0005] At present, the contrast agents on the Chinese market are mainly made by crushing, mixing and compounding locally available herbal medicines and raw materials. For example, the herbal preparations prepared by the herbal prescriptions listed in CN102441180B, CN103611173B, etc. have certain health management and treatment effects. The developing assistant listed in CN1721000A is made by crushing, mixing and blending the ingredients, and has a better ultrasound image display effect, but before use, it needs to be directly brewed with 90-100 ° C hot water, stirred rapidly to form a uniform paste solution, and then cooled to a suitable temperature (generally controlled at 30-50 ° C), and then given to the patient to drink or instructed to take it to perform ultrasound examination at the same time.

[0006] In addition to Chinese herbal medicines and foodstuffs auxiliary developers, more convenient and effective auxiliary developer technologies have been developed. For example, the auxiliary developer described in patent CN107115534A uses a combination of osmotic contrast agents, swelling substances, stabilizers and defoamers to obtain an auxiliary developer with good compatibility and good filling effect. Meanwhile, patent CN109745570A, in addition to the use of osmotic contrast agents, increases the solid contrast agent, improves the development effect, and introduces bioactive substances such as bioactive glass, oligofructose and hyaluronic acid to play a certain health management role.

[0007] However, no matter what kind of auxiliary developer, there are certain limitations. For example, traditional Chinese medicine auxiliary developer has good health care effect, but the display interface under ultrasound is a low echo interface, the effect of auxiliary development is limited, the operation is complicated, and the waiting time is long; auxiliary developer with added solid contrast must first have appropriate size of solid contrast particles, if the solid contrast particles are too small or too large, the development effect is not good; if the solid contrast particles are too small, the brightness of the development interface is too low; if the solid contrast particles are too large, the graininess of the development interface is too strong; and the solid contrast density must be consistent with the liquid system of the auxiliary developer, if the density is inconsistent, it will affect the uniformity of the product. , when the density is too high, the solid contrast in the liquid auxiliary developer is easy to sink; when the density is too low, the solid contrast in the liquid auxiliary developer is easy to float; finally, it is necessary to add a swelling material to the auxiliary developer to increase the window time; when the viscosity of the auxiliary developer system is high, it is difficult to discharge intragastric gas, which is easy to cause artifacts and affect the development effect; when the density of the solid contrast is too high or too low, it is difficult to shake evenly when sinking or floating occurs; when the viscosity of the auxiliary developer system is low, the window time is too short, and the stomach is easy to discharge the auxiliary developer quickly, which interferes with the clinician's gastric ultrasound diagnosis work. Summary of the Invention

[0008] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide a two-component gastric ultrasound examination auxiliary developer which has a stronger stomach wall development auxiliary effect, is a stable and uniform product, is easy to expel excess gas in the stomach during use, and can increase the window time.

[0009] To achieve the above objectives, the present invention adopts the following technical solutions: The two-component gastroultrasound auxiliary developer is composed of two components, component A and component B, component A is composed of functional silica particles, antifoaming agent, preservative, sodium alginate, citric acid and water, and component B is calcium chloride solution. The density of the functional silica particles is the same as the liquid density of component A of the auxiliary developer.

[0010] The present invention utilizes the characteristics of low viscosity and the presence of antifoaming agent of component A, which can quickly discharge gas while filling the stomach, reducing gas artifact interference, and with the gastric peristalsis, the functional silica particles can be quickly dispersed in the stomach wall, and under the action of aldehyde group or sulfhydryl group and alcohol-soluble protein, can adhere to the stomach wall lipoprotein layer, forming a uniform and highly echogenic interface in the stomach wall, and improving the diagnosis rate of diseases. After using component B, the viscosity of the auxiliary developer increases, which can increase the window time and ensure sufficient examination time.

[0011] Furthermore, the functional silica particles are silica particles modified with a biocompatible polymer, and the mass percentage of the present component A is 0.5 to 1.5%.

[0012] Furthermore, in the silica particles modified with a biocompatible polymer, the particle size of the silica is 70 to 90 mesh.

[0013] Furthermore, the defoaming agent is at least one of an organosilicon-based defoaming agent and a polyether-based defoaming agent, the organosilicon-based defoaming agent may be dimethylsiloxane, etc., and the polyether-based defoaming agent may be polyoxypropylene oxide ethylene glyceryl ether, etc. The mass percentage of the defoaming agent in component A is 0.02 to 0.04%.

[0014] Furthermore, the viscosity of a 1% aqueous solution of the sodium alginate is 100 to 200 mPa·s, and the mass percentage of sodium alginate in component A is 0.5 to 1%.

[0015] Furthermore, the mass percentage of the citric acid in component A is 4.2 to 6%.

[0016] Furthermore, the mass percentage concentration of the calcium chloride solution in component B is 12.5 to 18%.

[0017] Furthermore, the volume ratio of component A to component B of the co-developer is 9:1, and components A and B are packaged separately.

[0018] Furthermore, the mass ratio of citric acid to calcium chloride in the auxiliary developer is 3:1.

[0019] Furthermore, the preservative is sodium deoxyacetate, and the mass percentage of the preservative in component A is 0.03 to 0.05%.

[0020] Furthermore, the biocompatible polymer is one or more of polyethylene glycol, branched polyethylene glycol, chitosan, and hyaluronic acid.

[0021] Furthermore, the biocompatible polymer is graft-modified with an aldehyde group and an alcohol-soluble protein, or with a sulfhydryl group and an alcohol-soluble protein, the grafting rate of the aldehyde group or the sulfhydryl group accounts for 10-20% of the active groups of the biocompatible polymer, and the grafting rate of the alcohol-soluble protein accounts for 5-10% of the active groups of the biocompatible polymer.

[0022] Furthermore, the active groups of polyethylene glycol and branched polyethylene glycol are hydroxyl groups, the active groups of chitosan are amino groups, and the active groups of hyaluronic acid are carboxyl groups.

[0023] Furthermore, before components A and B of the auxiliary developer are mixed, the viscosity of component A is 100 mPa·s or less, and after components A and B are sufficiently mixed, the viscosity of the auxiliary developer is 500 mPa·s or more.

[0024] Furthermore, the preparation method of the above two-component gastric ultrasound examination auxiliary developer comprises the following steps: (1) Take purified water, add citric acid at 50-100 rpm, and after the citric acid has dissolved, adjust the rotation speed to 800-1200 rpm. Add sodium alginate in small amounts several times, then adjust the rotation speed to 30-60 rpm. Heat the solution to 90°C with continuous stirring, and after the sodium alginate has completely dissolved, adjust the rotation speed to 50-100 rpm. Then add functional silica particles, an antifoaming agent, and a preservative, and thoroughly mix the functional silica particles, antifoaming agent, and preservative with the solution to obtain component A.

[0025] (2) Dissolve calcium chloride in purified water at 50 to 100 rpm to obtain unsterilized component B. (3) Component A and unsterilized component B are placed in a polyester bottle, and the unsterilized component B is sterilized by electron beam irradiation at 15 to 25 K to obtain component B.

[0026] During the examination, component A with low viscosity is used first, which can fill the stomach and quickly discharge gas at the same time, reducing the interference of gas artifacts, and at the same time, the functional silica particles can quickly disperse in the stomach wall with the peristalsis of the stomach, and under the action of aldehyde groups or sulfhydryl groups and alcohol-soluble proteins, they can adhere to the lipoprotein layer of the stomach wall, forming a uniform and highly echogenic interface in the stomach wall, which can improve the diagnosis rate of diseases. After 3 minutes of using component A, component B can be used, and the viscosity of the auxiliary developer increases in 1 to 3 minutes, and the window time is extended, ensuring sufficient examination time. Effect of the Invention

[0027] The present invention has the following beneficial effects: 1. The auxiliary developer of the present invention has a good auxiliary development effect on the stomach wall. Through literature search, in vitro and in vivo verification, silica particles of a certain particle size are selected and modified with a biocompatible polymer grafted with a certain functional group, the silica particles use biocompatible polymers to increase the surface area, and the use of aldehyde groups or sulfhydryl groups and alcoholic proteins increases the adhesion of silica particles to the lipoprotein layer of the stomach wall, so that together with the peristalsis of the stomach, the functional silica particles can quickly disperse and adhere to the stomach wall, forming a uniform and highly echogenic interface, which can ensure the diagnosis of diseases. 2. The auxiliary developer of the present invention ensures uniform and stable products without the floating or falling of solid contrast. The silica particles modified with biocompatible polymer have the same density as the liquid density of component A, so that no settling or floating occurs during storage, ensuring the stability of the product. 3. The auxiliary developer of the present invention can ensure sufficient window time and at the same time discharge excess gas in the stomach, reducing the impact of gas artifacts on the gastric ultrasound diagnostic development auxiliary effect. The initial viscosity of component A is less than 100mPa·s, and contains antifoaming agent. After entering the stomach, it can quickly discharge gas while filling the stomach, reducing gas artifact interference; after using component B, under the action of citric acid and calcium ions, the cross-linking degree of sodium alginate is increased, the viscosity of the auxiliary developer increases, the window time is increased, and sufficient examination time can be ensured. [Brief description of the drawings]

[0028] [Figure 1] FIG. 2 shows the viscosity of a two-component gastric ultrasound examination auxiliary developer and its component A at 37±0.2° C. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] The present invention will be further described below with reference to examples. However, it should be noted that the following description is intended only to interpret the present invention and is not intended to limit the contents thereof.

[0030] Unless otherwise specified, in the silica particles modified with a biocompatible polymer used in the examples and comparative examples, the particle size of the silica is 70 to 90 mesh, the volume ratio of component A to component B in the auxiliary developer is 9:1, and the mass ratio of citric acid to calcium chloride in the auxiliary developer is 3:1.

[0031] Example 1 A certain amount of purified water is taken, and citric acid (mass fraction of citric acid in component A is 5%) is added at 50-100 rpm. After the citric acid is dissolved, the rotation speed is adjusted to 800-1200 rpm. Sodium alginate (mass fraction of sodium alginate in component A is 0.7%) with a viscosity of 1% aqueous solution of 150 mP·s is added in small amounts several times. Then, the rotation speed is adjusted to 30-60 rpm. The solution is heated to 90°C under continuous stirring. After the sodium alginate is completely dissolved, the rotation speed is adjusted to 50-100 rpm. Then, polyethylene glycol-functionalized silica particles (functional) with a grafting rate of sulfhydryl groups of 15% and a grafting rate of alcohol-soluble proteins of 7.5% are added. Functional silica particles are added to component A at a mass fraction of 1%, dimethylsiloxane (dimethylsiloxane has a mass fraction of 0.03% in component A) and sodium deoxyacetate (sodium deoxyacetate has a mass fraction of 0.04% in component A), and the functional silica particles, dimethylsiloxane, sodium deoxyacetate and the solution are thoroughly mixed to obtain component A, and the density of the functional silica particles is the same as the liquid density of component A. Calcium chloride (calcium chloride has a mass fraction of 15% in component B) is dissolved in purified water at 50 to 100 rpm to obtain unsterilized component B, and component A and unsterilized component B are placed in polyester bottles, and unsterilized component B is sterilized by irradiating it with an electron beam at 20 K to obtain component B.

[0032] Example 2 A certain amount of purified water is taken, and citric acid (citric acid has a mass fraction of 4.2% in component A) is added at 50-100 rpm. After the citric acid is dissolved, the rotation speed is adjusted to 800-1200 rpm. Sodium alginate (sodium alginate has a mass fraction of 0.5% in component A) with a viscosity of 200 mP·s in 1% aqueous solution is added in small amounts several times. The rotation speed is then adjusted to 30-60 rpm. The solution is heated to 90°C under continuous stirring. After the sodium alginate is completely dissolved, the rotation speed is adjusted to 50-100 rpm. Chitosan-functionalized silica particles (functionalized silica particles have a mass fraction of 0.5% in component A) with an aldehyde group grafting rate of 20% and an alcohol-soluble protein grafting rate of 5% are then added. Add polyoxypropylene oxide ethylene glyceryl ether (polyoxypropylene oxide ethylene glyceryl ether has a mass fraction of 0.02% in component A) and sodium deoxyacetate (sodium deoxyacetate has a mass fraction of 0.05% in component A), thoroughly mix the functional silica particles, polyoxypropylene oxide ethylene glyceryl ether, sodium deoxyacetate and the solution to obtain component A, the density of the functional silica particles being the same as the liquid density of component A, dissolve calcium chloride (calcium chloride has a mass fraction of 12.5% ​​in component B) in purified water at 50-100 rpm to obtain unsterilized component B, place component A and unsterilized component B, and component A and component B in a polyester bottle, irradiate unsterilized component B with an electron beam at 25K to sterilize it and obtain component B.

[0033] Example 3 A certain amount of purified water is taken, and citric acid (mass fraction of citric acid in component A is 6%) is added at 50-100 rpm. After the citric acid is dissolved, the rotation speed is adjusted to 800-1200 rpm. Sodium alginate (mass fraction of sodium alginate in component A is 1%) with a 1% aqueous solution viscosity of 100 mP·s is added in small amounts several times. The rotation speed is then adjusted to 30-60 rpm. The solution is heated to 90°C with continuous stirring. After the sodium alginate is completely dissolved, the rotation speed is adjusted to 50-100 rpm. Hyaluronic acid-functionalized silica particles (functionalized silica particles are component A) with a graft rate of sulfhydryl groups of 10% and a graft rate of alcohol-soluble proteins of 10% are then prepared. The functional silica particles, dimethylsiloxane, and sodium deoxyacetate are thoroughly mixed with the solution to obtain component A, and the density of the functional silica particles is the same as the liquid density of component A. Calcium chloride (calcium chloride has a mass fraction of 18% in component B) is dissolved in purified water at 50 to 100 rpm to obtain unsterilized component B. Component A and unsterilized component B, and component A and component B are placed in a polyester bottle, and unsterilized component B is irradiated with an electron beam at 15 K to sterilize it to obtain component B.

[0034] Example 4 The same as Example 1, except for the following: the functionalized silica particles are polyethylene glycol-functionalized silica particles with a grafting rate of sulfhydryl groups of 10% and a grafting rate of alcohol-soluble proteins of 5%, the mass fraction in component A is 0.5%, and the density of the functionalized silica particles is the same as the liquid density of component A.

[0035] Example 5 The same as Example 1, except for the following: the functionalized silica particles are polyethylene glycol-functionalized silica particles with a grafting rate of sulfhydryl groups of 20% and a grafting rate of alcohol-soluble proteins of 10%, the mass fraction in component A is 1.5%, and the density of the functionalized silica particles is the same as the liquid density of component A.

[0036] Example 6 This is the same as Example 1, except for the following: the mass fraction of sodium alginate in component A is 0.5%, and the viscosity of a 1% aqueous solution of sodium alginate is 200 mP·s.

[0037] Example 7 This is the same as Example 1, except for the following: the mass fraction of sodium alginate in component A is 1%, and the viscosity of a 1% aqueous sodium alginate solution is 100 mP·s.

[0038] Example 8 Same as Example 1, except for the following: sodium citrate has a mass fraction of 4.2% in component A, and calcium chloride has a mass fraction of 12.5% ​​in component B.

[0039] Example 9 Same as Example 1, except for the following: sodium citrate has a mass fraction of 6% in component A, and calcium chloride has a mass fraction of 18% in component B.

[0040] Comparative Example 1 Same as Example 1, with the following exceptions: the silica particles were not functionally modified.

[0041] Comparative Example 2 Same as Example 1, except: the silica particles are modified with polyethylene glycol, but the polyethylene glycol does not contain sulfhydryl groups and the grafting of alcohol-soluble proteins.

[0042] Comparative Example 3 The same as Example 1, except for the following: the silica particles are modified with polyethylene glycol, but the grafting rate of sulfhydryl groups of polyethylene glycol is 5%, and the grafting rate of alcohol-soluble protein is 2.5%.

[0043] Comparative Example 4 Same as Example 1, except for the following: Components A and B are provided in a mixed state.

[0044] Comparative Example 5 The same as Example 1, except for the following: the mass fraction of sodium alginate in component A is 0.2%.

[0045] Comparative Example 6 Same as Example 1, except: No antifoam agent added.

[0046] Silica particles modified with biocompatible polymers have been published in the following publications: "Research on the functionality of mesoporous silica nanomaterials and drug loading and in vitro release" (Wang Shuai. Research on the functionality of mesoporous silica nanomaterials and drug loading and in vitro release [D]. Guizhou University, 2020.), "Mesoporous silica nanoparticles dually modified with sulfhydryl and carboxyl groups and their preparation method" (CN107055553A), "Preparation of mesoporous silica nanoparticles modified with polyethylene glycol at the carboxyl end and their application" (CN108046276A), "Research on the support system based on mesoporous silica" (Shi Shaoming. Research on the support system based on mesoporous silica [D]. Changzhou University, 2021.), "Construction of aminated mesoporous silica / biopolymer-based drug release control system" (Li Shangji. Construction of drug release control system based on aminated mesoporous silica / biopolymer [D]. Changzhou University, 2021.), Pickering emulsion prepared from alginic acid derivative-activated silica nanoparticles (Cheng Chunfeng, Li Jiacheng, Yan Huiqiong, Liu Ruolin, Wang Chunxiu, Lin Qiang. Pickering emulsion prepared from alginic acid derivative-activated silica nanoparticles [J]. Daily Chemical Industry, 2014, 44(05):241-246.), etc.

[0047] According to "YY / T 0681.1~2018 Part 1 of the Test Method for Packaging of Sterile Medical Devices: Guide for Accelerated Aging Test", the gastric ultrasound auxiliary developer prepared in Examples 1~9 and Comparative Examples 1~6 was subjected to accelerated aging at 60℃ for 65 days with a target validity period of 2 years, and the uniformity of the sample after aging was recorded. The results are shown in Table 1 below.

[0048] [Table 1]

[0049] As can be seen from Table 1, the samples of Examples 1 to 9, Comparative Example 2, Comparative Example 3, Comparative Example 5, and Comparative Example 6 were uniform even after accelerated aging, and did not have the problem of solid particle floating or settling. The silica particles in Comparative Example 1 were not functionally modified, and their density was greater than the liquid density of component A, so the solid particle settling phenomenon occurred. In Comparative Example 4, components A and B were stored in a mixed state, and although the overall viscosity was high at first, the sample maintained a more durable uniformity, and after complete aging, the functional silica particles finally had a smaller density than the mixed solution, so the solid particle floating phenomenon occurred.

[0050] As shown in FIG. 1, the viscosity of the gastric ultrasound examination auxiliary developer after mixing the component A and the two components of Examples 1 to 9 and Comparative Examples 1 to 6 was measured at 37±0.2° C.

[0051] As can be seen from FIG. 1, at 37±0.2°C, the viscosities of component A in Examples 1-9, Comparative Examples 1-3, and Comparative Examples 5-6 are all less than 100 mPa s, and the viscosities after mixing the components in Examples 1-9, Comparative Examples 1-4, and Comparative Example 6 are all greater than 500 mPa s. Comparative Example 4 is a two-component mixed sample and there is no viscosity data related to component A. The concentration of sodium alginate in Comparative Example 5 is too low, and the two-component mixing does not achieve the viscosity requirement of 500 mPa s or more.

[0052] The development effects of the gastric ultrasound examination auxiliary developers prepared in Examples 1 to 3 and Comparative Examples 1 to 6 were detected, and the specific methods are as follows: In addition to the sample described in Comparative Example 4, four bottles of 450 ml component A sample and 50 ml component B sample were prepared for each group, and four bottles of two-component mixed sample were prepared for the sample described in Comparative Example 4. The experimental animals were four beagle dogs, 2 females / 2 males, 9 to 11 months old, weighing about 10 kg. In addition to the sample group described in Comparative Example 4, in other groups, 450 ml of component A sample was orally administered 15 minutes before the imaging test, and 50 ml of component B sample was orally administered 3 minutes later, and the stomach filling state was observed by ultrasound examination 3 minutes after the administration of component B. In the sample group described in Comparative Example 4, 500 ml was directly administered, and the stomach filling state was observed 6 minutes after administration.

[0053] The scores were based on the hierarchy and structure of the stomach wall, stomach morphology, expression of peristaltic emptying function, window time satisfaction, and gas artifact removal effect. The score standards are shown in Table 2 below, with higher scores indicating better performance.

[0054] [Table 2]

[0055] The development effects of Examples 1 to 3 and Comparative Examples 1 to 6 are shown in detail in Table 3 below.

[0056] [Table 3]

[0057] As can be seen from Table 3, the average scores of Examples 1 to 3 are all above 5.5. As can be seen from the scores of each item, the sample development effects described in Examples 1 to 3 are as follows: the gastrointestinal wall hierarchy and structure, the morphology of each part of the gastrointestinal tract, the gastrointestinal peristalsis and excretion function can be fully recognized, the gas artifacts can be almost completely removed, and sufficient stomach window time can be ensured to meet the normal speed observation. The average scores of Comparative Examples 1 to 6 were 3.05, 4.35, 4.6, 4, 5.2 and 5.05, respectively, which were much lower than the scores of Examples 1 to 3. As can be seen from the scores of each item, the silica particles of Comparative Example 1 have no functionality. After component A enters the stomach, it can only form specific adhesion with the stomach wall, and after component B enters, it can only float in the stomach cavity. The content of the silica particles themselves is low, so the score of the gas artifact removal effect is good, but the other scores are much lower than those of Examples 1 to 3. In Comparative Example 2, the silica particles are not modified with specific functional groups compared to Comparative Example 1, but are modified with biocompatible polymers, and their density is close to that of the sample liquid. In addition to the score of the gas artifact removal effect, all other scores are improved. In Comparative Example 3, the silica particles are modified with a certain amount of specific functional groups compared to Comparative Example 2. However, since the functional group content is lower than those of Examples 1 to 3, the score is between Comparative Example 2 and Examples 1 to 3. Comparative Example 4 is a two-component premix sample, and the initial viscosity in the stomach is high and gas cannot be discharged. At the same time, the rate at which the functional silica particles adhere to the stomach wall is low, so the stomach wall hierarchical structure, the satisfaction level of the effective examination window time, and the gas artifact removal effect are lower than those of Examples 1 to 3. Comparative Example 5 has a low content of sodium alginate, and can discharge gas in the stomach well and the functional silica particles can adhere well to the stomach wall, but its final viscosity is low and the effective examination window time cannot be satisfied. Comparative Example 6 does not have an antifoaming agent, so the gas artifact removal effect is poor.

[0058] The above-described embodiments are only some of the embodiments of the present invention, but not all of the embodiments. The detailed description of the embodiments of the present invention does not limit the scope of the present invention, but is intended to represent only selected embodiments of the present invention. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative labor are all included in the protection scope of the present invention.

Claims

1. The developer is made of two components, component A is made of functional silica particles, an antifoaming agent, a preservative, sodium alginate, citric acid and water, and component B is a calcium chloride solution, the density of the functional silica particles is the same as the liquid density of component A of the auxiliary developer, the functional silica particles are silica particles modified with a biocompatible polymer, the mass percentage in component A is 0.5-1.5%, in the silica particles modified with a biocompatible polymer, the particle size of the silica is 70-90 mesh, the biocompatible polymer is one or more of polyethylene glycol, branched polyethylene glycol, chitosan and hyaluronic acid, the biocompatible polymer is graft-modified with an aldehyde group and an alcohol-soluble protein, or graft-modified with a sulfhydryl group and an alcohol-soluble protein, and the aldehyde group or the sulfhydryl group is graft-modified with an alcohol-soluble protein. a graft rate of alcohol-soluble protein occupies 10-20% of the active groups of the biocompatible polymer, a graft rate of alcohol-soluble protein occupies 5-10% of the active groups of the biocompatible polymer, the active groups of polyethylene glycol and branched polyethylene glycol are hydroxyl groups, the active group of chitosan is an amino group, and the active group of hyaluronic acid is a carboxyl group, the mass percentage of sodium alginate in component A is 0.5-1% and the viscosity of a 1% aqueous solution thereof is 100-200 mPa·s, the mass percentage of citric acid in component A is 4.2-6%, and the mass percentage concentration of calcium chloride solution in component B is 12.5-18%, the volume ratio of components A and B in the auxiliary developer is 9:1, and the mass ratio of citric acid to calcium chloride in the auxiliary developer is 3:

1.

2. The two-component stomach ultrasound examination auxiliary developer according to claim 1, characterized in that the antifoaming agent is at least one of an organosilicon-based antifoaming agent and a polyether-based antifoaming agent, and the mass percentage of the antifoaming agent in component A is 0.02 to 0.04%.

3. 3. The two-component stomach ultrasound examination auxiliary developer according to claim 2, wherein the organosilicon-based antifoaming agent is dimethylsiloxane, and the polyether-based antifoaming agent is polyoxypropylene oxide ethylene glyceryl ether.

4. The two-component stomach ultrasound examination auxiliary developer according to claim 1, characterized in that the preservative is sodium deoxyacetate, and its mass percentage in component A is 0.03-0.05%.

5. The two-component auxiliary developer for gastric ultrasound examination according to any one of claims 1 to 4, characterized in that before components A and B of the auxiliary developer are mixed, the viscosity of component A is 100 mPa·s or less, and after components A and B are sufficiently mixed, the viscosity of the auxiliary developer is 500 mPa·s or more.

6. A method for preparing the two-component stomach ultrasound examination auxiliary developer according to any one of claims 1 to 5, comprising the steps of: collecting purified water, adding citric acid at 50-100 rpm, adjusting the rotation speed to 800-1200 rpm after the citric acid is dissolved, adding sodium alginate in small amounts several times, adjusting the rotation speed to 30-60 rpm, heating the solution to 90°C while continuously stirring, adjusting the rotation speed to 50-100 rpm after the sodium alginate is completely dissolved, adding functional silica particles, antifoaming agent and preservative, and thoroughly mixing the functional silica particles, antifoaming agent, preservative and solution to obtain component A; dissolving calcium chloride in purified water at 50-100 rpm to obtain non-sterilized component B; putting component A and non-sterilized component B into polyester bottles respectively; and sterilizing the non-sterilized component B by irradiating with an electron beam at 15-25K to obtain component B.

Citation Information

Patent Citations

  • Mercapto-carboxyl dual-modified mesoporous silica nanoparticles and preparation method therefor

    CN107055553A

  • Preparation method and application of carboxyl terminated polyethylene glycol modified mesoporous silica nano particles

    CN108046276A

  • Targeted Porous Inorganic Ultrasound Contrast Agent

    JP2003504419A